8ct6
From Proteopedia
(Difference between revisions)
| Line 8: | Line 8: | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8ct6 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8ct6 OCA], [https://pdbe.org/8ct6 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8ct6 RCSB], [https://www.ebi.ac.uk/pdbsum/8ct6 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8ct6 ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8ct6 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8ct6 OCA], [https://pdbe.org/8ct6 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8ct6 RCSB], [https://www.ebi.ac.uk/pdbsum/8ct6 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8ct6 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Influenza virus poses an ongoing human health threat with pandemic potential. Due to mutations in circulating strains, formulating effective vaccines remains a challenge. The use of computationally optimized broadly reactive antigen (COBRA) hemagglutinin (HA) proteins is a promising vaccine strategy to protect against a wide range of current and future influenza viruses. Though effective in preclinical studies, the mechanistic basis driving the broad reactivity of COBRA proteins remains to be elucidated. Here, we report the crystal structure of the COBRA HA termed P1 and identify antigenic and glycosylation properties that contribute to its immunogenicity. We further report the cryo-EM structure of the P1-elicited broadly neutralizing antibody 1F8 bound to COBRA P1, revealing 1F8 to recognize an atypical receptor binding site epitope via an unexpected mode of binding. | ||
| + | |||
| + | Structural insights into the broad protection against H1 influenza viruses by a computationally optimized hemagglutinin vaccine.,Dzimianski JV, Han J, Sautto GA, O'Rourke SM, Cruz JM, Pierce SR, Ecker JW, Carlock MA, Nagashima KA, Mousa JJ, Ross TM, Ward AB, DuBois RM Commun Biol. 2023 Apr 25;6(1):454. doi: 10.1038/s42003-023-04793-3. PMID:37185989<ref>PMID:37185989</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 8ct6" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
Revision as of 11:59, 23 October 2024
1F8 mAb in complex with the computationally optimized broadly reactive H1 influenza hemagglutinin P1
| |||||||||||
